Sarepta Therapeutics Inc SRPT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:20 PM EDT
116.55UNCH (UNCH)
Volume
88,032
Close
116.55quote price arrow down-1.34 (-1.14%)
Volume
410,494
52 week range
55.25 - 159.89
Loading...
  • Open117.55
  • Day High118.90
  • Day Low115.79
  • Prev Close117.89
  • 52 Week High159.89
  • 52 Week High Date05/15/23
  • 52 Week Low55.25
  • 52 Week Low Date10/31/23

Key Stats

  • Market Cap10.939B
  • Shares Out93.86M
  • 10 Day Average Volume0.57M
  • Dividend-
  • Dividend Yield-
  • Beta0.97
  • YTD % Change20.86

KEY STATS

  • Open117.55
  • Day High118.90
  • Day Low115.79
  • Prev Close117.89
  • 52 Week High159.89
  • 52 Week High Date05/15/23
  • 52 Week Low55.25
  • 52 Week Low Date10/31/23
  • Market Cap10.939B
  • Shares Out93.86M
  • 10 Day Average Volume0.57M
  • Dividend-
  • Dividend Yield-
  • Beta0.97
  • YTD % Change20.86

RATIOS/PROFITABILITY

  • EPS (TTM)-6.15
  • P/E (TTM)-18.95
  • Fwd P/E (NTM)56.88
  • EBITDA (TTM)-223.427M
  • ROE (TTM)-86.15%
  • Revenue (TTM)1.243B
  • Gross Margin (TTM)87.91%
  • Net Margin (TTM)-43.11%
  • Debt To Equity (MRQ)144.06%

EVENTS

  • Earnings Date04/30/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sarepta Therapeutics Inc

 

Profile

MORE
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and...
M. Kathleen Behrens Ph.D.
Independent Chairwoman of the Board
Douglas Ingram Esq., J.D.
President, Chief Executive Officer, Director
Ian Estepan
Chief Financial Officer, Executive Vice President
Bilal Arif
Executive Vice President - Strategy and Operations, Chief Technical Operations Officer
Louise Rodino-Klapac Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R and D
Address
215 1st St Ste 415
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
NTRA
Natera Inc
87.28-3.05-3.38%
MEDP
Medpace Holdings Inc
374.32-8.12-2.12%
NBIX
Neurocrine Biosciences Inc
132.54-0.69-0.52%
EXAS
Exact Sciences Corp
63.48+0.26+0.41%
EXEL
Exelixis Inc
22.49-0.38-1.66%